Optivar and Singulair drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Optivar (azelastine hydrochloride) and Singulair (montelukast sodium). Common drug interactions include dissociation among females and visual field defect among males.

The phase IV clinical study analyzes what interactions people have when they take Optivar and Singulair. It is created by eHealthMe based on reports of 64 people who take the same drugs from the FDA, and is updated regularly.

What is Optivar?

Optivar has active ingredients of azelastine hydrochloride. eHealthMe is studying from 367 Optivar users. Check the latest studies of Optivar.

What is Singulair?

Singulair has active ingredients of montelukast sodium. It is often used in asthma. eHealthMe is studying from 129,752 Singulair users. Check the latest studies of Singulair.



On Jul, 06, 2026

64 people who take Optivar and Singulair together, and have interactions are studied.

Optivar and Singulair drug interactions.

What are the common drug interactions of Optivar and Singulair, by gender? *:

female:

  1. Dissociation
  2. Drug effect delayed
  3. Drug intolerance (drug sensitivity)
  4. Dry eye (lack of adequate tears)
  5. Dry mouth
  6. Dyspnoea (difficult or laboured respiration)
  7. Ear disorder
  8. Embolism arterial (blood clot that has travelled through your arteries and become stuck)
  9. Epistaxis (bleed from the nose)
  10. Eye discharge

male:

  1. Visual field defect
  2. Abnormal behaviour
  3. Epistaxis (bleed from the nose)
  4. Glaucoma (increased fluid pressure in the eye with vision loss)
  5. Haematuria (presence of blood in urine)
  6. Haemoglobin decreased
  7. Hypersensitivity
  8. Influenza like illness
  9. Loss of consciousness
  10. Peritonsillar abscess (painful pus filled inflammation of the tonsils and surrounding tissues)

What are the common drug interactions of Optivar and Singulair, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Suicidal ideation
  2. Visual field defect
  3. Abdominal pain upper
  4. Aggression
  5. Depression
  6. Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
  7. Influenza
  8. Intraocular pressure increased
  9. Self-injurious ideation
  10. Glaucoma (increased fluid pressure in the eye with vision loss)

10-19:

  1. Abnormal behaviour
  2. Biliary colic
  3. Cholecystitis chronic (long lasting infection of gallbladder)
  4. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
  5. Suicide attempt
  6. Gallbladder disorder
  7. Injection site erythema (redness at injection site)
  8. Injection site oedema
  9. Injection site pruritus (severe itching at injection site)

20-29:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  2. Aphasia (damage to the parts of the brain that control language)
  3. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  4. Complex partial seizures (epileptic seizure)
  5. Confusional state
  6. Deja vu (the experience of thinking that a new situation had occurred before)
  7. Depression
  8. Device expulsion
  9. Dissociation
  10. Dysphonia (speech disorder attributable to a disorder of phonation)

30-39:

  1. Pain
  2. Pain in extremity
  3. Pain of skin
  4. Paranasal sinus discomfort
  5. Productive cough
  6. Pruritus (severe itching of the skin)
  7. Rash erythematous (redness of the skin)
  8. Sinus headache (headache caused by sinus infections)
  9. Snoring
  10. Surgery

40-49:

  1. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)
  2. Sinusitis (inflammation of sinus)
  3. Candidiasis (candidiasis or thrush is a fungal infection)
  4. Skin irritation
  5. Sunburn
  6. Upper respiratory tract infection
  7. Dermatitis atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder)
  8. Pain
  9. Erythema (redness of the skin)
  10. Skin disorder (skin disease)

50-59:

  1. Fall
  2. Femur fracture
  3. Pain in extremity
  4. Stress fracture (fracture of a bone caused by repeated (rather than sudden) mechanical stress)
  5. Bone disorder
  6. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  7. Gait disturbance
  8. Haematochezia (passage of stools containing blood)
  9. Headache (pain in head)
  10. Increased tendency to bruise (increased tendency to injure the underlying soft tissue or bone)

60+:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)
  3. Dyspepsia (indigestion)
  4. Ear disorder
  5. Erythema (redness of the skin)
  6. Flushing (the warm, red condition of human skin)
  7. Haematochezia (passage of stools containing blood)
  8. Muscle spasms (muscle contraction)
  9. Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
  10. Ovarian cancer metastatic (cancer of ovary spreads to other organ or parts)

What are the existing conditions these people have? *

  1. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 7 people, 10.94%
  2. Hypersensitivity: 6 people, 9.38%
  3. Birth Control: 6 people, 9.38%
  4. Pain: 5 people, 7.81%
  5. Multiple Allergies (allergy to multiple agents): 5 people, 7.81%
  6. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 5 people, 7.81%
  7. The Flu (the flu is caused by an influenza virus): 4 people, 6.25%
  8. Migraine (headache): 4 people, 6.25%
  9. Immunodeficiency: 4 people, 6.25%
  10. Depression: 4 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Optivar and Singulair?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Optivar and Singulair:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Optivar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Singulair:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Optivar and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Singulair and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on azelastine hydrochloride and montelukast sodium (the active ingredients of Optivar and Singulair, respectively), and Optivar and Singulair (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: